A Multicenter, Randomized, Open‐Label, Active‐Controlled, Parallel Study to Assess the Efficacy and Safety of Ferric Citrate Capsules for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Ferric citrate (Primary) ; Sevelamer
- Indications Hyperphosphataemia
- Focus Registrational; Therapeutic Use
- Sponsors Panion & BF Biotech
Most Recent Events
- 08 Mar 2021 Status changed from recruiting to completed.
- 10 Aug 2020 Planned End Date changed from 20 Oct 2020 to 31 Dec 2020.
- 10 Aug 2020 Planned primary completion date changed from 30 Jun 2020 to 30 Nov 2020.